Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous furosemide Clear all
Not yet recruiting Phase 4 Interventional

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

NCT07167862
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild
Interventions
Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide
Diagnostic Test · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Protocolized Diuretic Strategy in Cardiorenal Failure

NCT01921829
View directory record Official record
Conditions
Cardiac Failure, Renal Failure, Kidney Failure
Interventions
Protocolized Diuretic Strategy
Drug
Lead sponsor
Kelly V. Liang, MD
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics

NCT01457053
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

NCT00904488
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Addition of oral Metolazone, Furosemide dose escalation
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

NCT02527798
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 6, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Effect of Giving Reduced Fluid in Children After Trauma

NCT04201704
View directory record Official record
Conditions
Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions
Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 15 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Buffalo, New York • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional

Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury

NCT01073189
View directory record Official record
Conditions
Kidney Failures, Acute
Interventions
Intra-Renal Fenoldopam, Furosemide
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

NCT03746002
View directory record Official record
Conditions
Fluid Overload, Heart Failure Acute
Interventions
Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 6, 2026, 8:23 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety

NCT03946891
View directory record Official record
Conditions
Premature Birth, Premature Infant
Interventions
Inhaled Furosemide, Intravenous Furosemide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
0 Years to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Aerosol Inhalation Treatment for Dyspnea

NCT01440764
View directory record Official record
Conditions
Healthy, Dyspnea
Interventions
Furosemide, Saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

AiDing Diuresis wIth Tolvaptan (ADD-IT)

NCT02646540
View directory record Official record
Conditions
Cardiomyopathy, Congestive Heart Failure
Interventions
Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

NCT01474200
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
Interventions
Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
Device · Drug
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
38
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT02329834
View directory record Official record
Conditions
Heart Failure
Interventions
Fursemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

NCT03136198
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions
LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
Other · Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 6, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional

Combination Diuretic Therapy for Acute Decompensated Heart Failure

NCT05840536
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide plus Chlorothiazide, Furosemide
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis

NCT02469597
View directory record Official record
Conditions
Bronchiolitis
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
Up to 48 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ultra High Dose Diuretics to Treat Heart Failure

NCT06036914
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
Bumetanide, Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers

NCT06167707
View directory record Official record
Conditions
Heart Failure, Fluid Overload
Interventions
SCP-111, Furosemide USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

NCT02546583
View directory record Official record
Conditions
Heart Failure
Interventions
Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide), IV Chlorothiazide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT04384653
View directory record Official record
Conditions
Heart Failure
Interventions
Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump
Drug · Device
Lead sponsor
SQ Innovation, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

NCT02356159
View directory record Official record
Conditions
Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound

NCT05098366
View directory record Official record
Conditions
Ovarian Torsion
Interventions
Furosemide, Normal saline
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 6, 2026, 8:23 AM EDT